Loading...
XSTO
FLUI
Market cap5mUSD
, Last price  
SEK
Name

Fluicell AB

Chart & Performance

D1W1MN
XSTO:FLUI chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
181.67%
Rev. gr., 5y
5.31%
Revenues
6m
+222.86%
140,268140,2681,415,8102,635,0001,052,0001,226,0002,488,0004,635,0002,602,0003,251,0003,338,0001,859,0006,002,000
Net income
-8m
L-46.28%
-1,646,881-1,646,881-3,783,421-4,950,000-7,470,000-14,700,000-18,635,000-18,154,000-21,720,000-21,487,000-26,554,000-15,511,000-8,332,000
CFO
-5m
L-68.44%
000-5,497,000-7,831,000-12,462,000-17,069,000-17,569,000-18,640,000-21,043,000-27,227,000-15,669,000-4,945,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Fluicell AB (publ) is a global provider of cutting-edge single-cell discovery platforms, catering to applications in biomedicine, drug development, and bioprinting. The company's product line includes the BioPen PRIME and BioPen FLEX microfluidic systems, engineered for precise localized solution delivery during single-cell experiments and for managing the chemical microenvironment of individual intact cells within tissue or cell cultures. Furthermore, Fluicell offers the Dynaflow Resolve system, a specialized platform for secondary ion channel screening that enables the measurement of various ion channel currents in a patch-clamp recording configuration. This Swedish company, headquartered in Gothenburg, was founded in 2012.
URL
https://fluicell.com/
IPO date
Apr 18, 2018
Employees
20
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT